Clear All
773 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9477 Elotuzumab Empliciti 1 mg Immunotherapy Monoclonal Antibody SLAMF7 No 2015 Jul 1, 2016 Dec 31, 2016 No Longer Used
J9061 Amivantamab Rybrevant 2mg Immunotherapy Monoclonal Antibody EGFR, MET No 2021 Jan 26, 2022 In Use
J9039 Blinatumomab Blincyto 1 mcg Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) No 2014 Jan 1, 2016 In Use
J9015 Aldesleukin Proleukin Per single vial (1 vial = 22 million IU) Immunotherapy Cytokine Interleukin-2 No 1992 Oct 1, 1996 In Use
J9329 Tislelizumab-jsgr Tevimbra 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2024 Sep 11, 2024 In Use
C9307 Linvoseltamab-gcpt Lynozyfic 1mg Immunotherapy Bispecific Antibody BCMA, CD3 No 2025 Jan 1, 2026 In Use
J9321 Epcoritamab-bysp Epkinly 0.16mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Dec 7, 2023 In Use
J9144 Daratumumab, hyaluronidase-fihj Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Jan 1, 2021 In Use
C9476 Daratumumab Darzalex 10 mg Immunotherapy Monoclonal Antibody CD38 No 2015 Jul 1, 2016 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
S9338 Immunotherapy - non specific Home infusion therapy, immunotherapy NA Immunotherapy No Jan 1, 2002 In Use
NA Thalidomide Thalomid 50 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Thalidomide Thalomid 200 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
J9275 Cosibelimab-ipdl UNLOXCYT 2mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2025 Jul 9, 2025 In Use
C9284 Ipilimumab Yervoy 1mg Immunotherapy Checkpoint Inhibitor CTLA-4 No 2011 Jul 1, 2011 Dec 31, 2011 No Longer Used
Q5158 Denosumab-bnht Bomyntra, Conexxence 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Sep 8, 2025 In Use
J9301 Obinutuzumab Gazyva 10 mg Immunotherapy Monoclonal Antibody CD20 No 2013 Jan 1, 2015 In Use
C9081 Idecabtagene vicleucel Abecma up to 460000000 Immunotherapy CAR-T BCMA No 2021 Sep 27, 2021 Jan 26, 2022 No Longer Used
Q2043 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Jul 1, 2011 In Use
J9353 Margetuximab-cmkb Margenza 5mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 23, 2021 In Use
J9303 Panitumumab Vectibix 10mg Immunotherapy Monoclonal Antibody EGFR No 2006 Jan 1, 2008 In Use
J9024 Atezolizumab, hyaluronidase-tqjs Tecentriq Hybreza 5mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2024 Mar 26, 2025 In Use
C9025 Ramucirumab Cyramza 5 mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Oct 1, 2014 Dec 31, 2015 No Longer Used
J0202 Alemtuzumab Lemtrada 1 mg Immunotherapy Monoclonal Antibody CD52 No 2001 Jan 1, 2016 In Use
J9350 Mosunetuzumab-axgb Lunsumio 1mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2022 Jul 11, 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.